Tag: Metastatic Breast Cancer
FDA Approves First Diagnostic Tests to Identify HER2-positive Metastatic Breast Cancer...
The U.S. Food and Drug Administration (FDA) has approved additional indications for the Roche PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and VENTANA HER2 Dual ISH DNA Probe Cocktail tests.
Japan Approves Datopotamab Deruxtecan for the Treatment of Adult Patients with...
Datopotamab deruxtecan (Datroway®; Daiichi Sankyo, previously known as DS-1062 and TROP2 ADC, see ADC Drug Map) an antibody-drug conjugate or ADC, being jointly developed and commercialized globally by Daiichi Sankyo and AstraZeneca, has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.
Seattle Genetics Enhances Portfolio of Solid Tumor Programs by Acquiring Cascadian...
Two Washington-state based companies, Seattle Genetics and Cascadian Therapeutics (previously named Oncothyreon), a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the...
Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...
Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...
About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...
2017 San Antonio Breast Cancer Symposium will Highlight Several Antibody-Drug Conjugates...
This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad...
Pivotal Phase II Study of DS-8201 in Patients with HER2-Positive Metastatic...
Researchers at Daichi Sankyo initiation the DESTINY-Breast01, a pivotal phase II study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody-drug conjugate...
Growing Drug Development Outsourcing Expected to Increase Demand for Antibody-drug Conjugates
A recent research report published by Technavio, a leading global technology research and advisory company, confirms that the global antibody-drug conjugates (ADC) market will grow...
SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...
Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...
Antibody-drug Conjugate Potential for Metastatic Breast Cancer Treatment Shown Through Results...
In 2012, an estimated 2,975,314 women were living with breast cancer, representing about 12% of all new cancer cases and 25% of all cancers...
